Dr. Babak Razavi, MD, PhD

Dr. Razavi practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Razavi's NPI, 1851533855, was assigned on April 6, 2009. Dr. Razavi graduated from University of Rochester Medical Center in 2009. Dr. Razavi holds California license A115797.

Dr. Razavi's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Razavi's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Razavi is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Razavi to 1 more hospital and 1 medical group, each named with a free account. Dr. Razavi's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razavi practices, 3 sites in all. Vendor and product names are available with a free account.

Epilepsy is Dr. Razavi's primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dr. Razavi is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dr. Razavi is licensed in California.

Dmand AI lists epilepsy and seizures among the conditions Dr. Razavi treats.

CMS data shows 347 Medicare services from Dr. Razavi across 7 procedure codes in 2024, for 208 Medicare patients. Medicare paid $39,733 for them.

CMS counts 208 Medicare patients who saw Dr. Razavi in 2024. The largest group is under 65, with 65 patients. 65% of them have high cholesterol, and 62% have high blood pressure. 42% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Razavi's median patient age at 43, with 47% women.

In 2024, Dr. Razavi wrote 1,214 Medicare Part D claims for 124 patients. 75% of them were for generic drugs. CMS names the drug for 1,143 of them, across 28 drugs with 11 or more claims each, at $660,737 in total drug cost. In 2023, CMS named 897 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Razavi for performance year 2024, reported as part of a group. Dr. Razavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Razavi as offering telehealth.

Dmand AI links 23 papers to Dr. Razavi, published from 2009 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Electroencephalography, Epilepsies, Partial and Epilepsy. Dr. Razavi has published most often in Clin Neurophysiol. Dr. Razavi's most frequent co-authors are Kimford Jay Meador, MD, Josef Parvizi, MD, PhD and Robert Scott Fisher, MD.

CMS Open Payments shows 22 general payments to Dr. Razavi from 4 drug and device companies from 2016 to 2024. Education make up the largest share, 84% of the total. Neuropace, Inc. paid the most, $4,563. It also lists 345 research payments totaling $144,480 from 2019 to 2025.

Dr. Razavi graduated from University of Rochester Medical Center in 2009.

Dr. Razavi is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.